2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-P2632A
    RAD16-I hydrochloride 2100275-49-6 98.88%
    RAD16-I hydrochloride, a soft nanofibrous self-assembling peptide, is a suitable microenvironment for human mesenchymal stem cells’ (hMSC) proliferation and differentiation into chondrocytes. RAD16-I is a well-studied ionic complementary peptide was used as a model to check potential amyloid-like staining properties of SAPNFs.
    RAD16-I hydrochloride
  • HY-P2632C
    RAD16-I, free acid TFA 98.11%
    RAD16-I, free acid TFA is a derivative of RADA16 (HY-P2632), with no Ac and NH2 modifications at both ends, and it has the same function as RADA16. RAD16-I, free acid TFA is a non-directed self-assembling peptide hydrogel. Under physiological conditions, RAD16-I, free acid TFA spontaneously forms a three-dimensional nanofiber network that mimics the extracellular matrix, and possesses excellent properties such as high water content, biocompatibility and degradability. RAD16-I, free acid TFA serves as an ideal scaffold for three-dimensional cell culture. RAD16-I, free acid TFA not only maintains cell viability and induces self-organization, but also supports cell adhesion, proliferation, differentiation and insulin secretion, effectively stabilizes islet clusters and promotes directed differentiation of the cardiac lineage. RAD16-I, free acid TFA can construct a cell-friendly nano-microenvironment for research related to diseases such as myocardial infarction and diabetes.
    RAD16-I, free acid TFA
  • HY-P2932A
    Cholecystokinin-33 free acid
    Cholecystokinin-33 free acid is an analogue of Cholecystokinin (HY-P2932). C-terminal amidation is important for binding of Cholecystokinin to its receptors, and removing the amide group would decrease Cholecystokinin activity. Cholecystokinin-33 free acid can be used to study C-terminal amidation of Cholecystokinin-33.
    Cholecystokinin-33 free acid
  • HY-P2936A
    Sphingomyelin phosphodiesterase, Bacillus cereus 9031-54-3
    Sphingomyelin phosphodiesterase, Bacillus cereus is a sphingomyelin hydrolase and Insecticide. Sphingomyelin phosphodiesterase, Bacillus cereus catalyzes the decomposition of sphingomyelin into ceramide and phosphorylcholine. Sphingomyelin phosphodiesterase, Bacillus cereus causes rapid paralysis and death in injected insects, including German cockroaches and black cutworms. Sphingomyelin phosphodiesterase, Bacillus cereus reduces H2O2 production. Sphingomyelin phosphodiesterase, Bacillus cereus can be used in studies related to sepsis and endophthalmitis.
    Sphingomyelin phosphodiesterase, Bacillus cereus
  • HY-P3019A
    Urocortin III (human) TFA
    Urocortin III (human) TFA is a corticotropin-releasing factor (CRF)-related peptide. Urocortin III (human) TFA preferentially binds and activates CRF-R2 and has a discrete central nervous system and peripheral distribution. Urocortin III (human) TFA potently binds to type 2 CRF receptors, specifically mCRF2β (Ki = 13.5 nM) and rCRF2α (Ki = 21.7 nM), while demonstrating negligible affinity for hCRF1 (Ki >100 nM). Urocortin III (human) TFA mediates somatostatin-dependent negative feedback control of Insulin (human) (HY-P0035) secretion.
    Urocortin III (human) TFA
  • HY-P3223A
    Biphalin acetate 98%
    Biphalin acetate, a BBB-penetrable opioid peptide analog, contains two active enkephalin pharmacophores.Biphalin acetate has high affinity for opioid receptors. Biphalin acetate shows analgesic effect in acute, neuropathic, and chronic animal pain models. Biphalin acetate is also an antiviral, antiproliferative, anti-inflammatory, and neuroprotective agent.
    Biphalin acetate
  • HY-P3869A
    Lumekefamide TFA 98.59%
    Lumekefamide TFA ([D-Arg2]Dermorphin-(1-4) amide TFA) is a N-terminal shorter peptide amide of [D-Arg2]dermorphin with the hypothermic effect. Lumekefamide shows analgesic activity and degradation in soluble mouse liver and brain extracts.
    Lumekefamide TFA
  • HY-P3895A
    Substance P (3-11) acetate
    Substance P (3-11) acetate is a substance P (SP) fragment peptide that can cross the BBB. Substance P (3-11) acetate has contracting activities on guinea pig ileum. Substance P (3-11) acetate also promotes human monocyte chemotaxis.
    Substance P (3-11) acetate
  • HY-P3965A
    16-38-Thymosin β4 (cattle) TFA 98.14%
    16-38-Thymosin β4 (cattle) TFA is a Ca2+-independent MLCK activator with high affinity.
    16-38-Thymosin β4 (cattle) TFA
  • HY-P4106A
    Tat-GluR23Y, scrambled TFA 99.43%
    Tat-GluR23Y, scrambled TFA is the scrambled peptide of Tat-GluR23Y (HY-P2259). Tat-GluR23Y is a synthetic peptide containing tyrosine residues that inhibit AMPAR endocytosis and is effective in the research of long-term depression (LTD).
    Tat-GluR23Y, scrambled TFA
  • HY-P5154A
    Tamapin TFA 98.79%
    Tamapin TFA is a venom peptide, targeting to small conductance Ca(2+)-activated K(+) (SK) channels. Tamapin TFA is a selctive blocker of SK2 (Potassium Channel). Tamapin TFA inhibits SK channel-mediated currents in pyramidal neurons of the hippocampus. Tamapin TFA can be isolated from the Indian red scorpion (Mesobuthus tamulus).
    Tamapin TFA
  • HY-P5160A
    Phlotoxin-1 TFA
    Phlotoxin-1 (PhlTx1) is a 34-amino acid and 3-disulfide bridge peptide. Phlotoxin-1 can be isolated from Phlogiellus genus spider. Phlotoxin-1 is an antinociceptive agent by inhibiting NaV1.7 channel.
    Phlotoxin-1 TFA
  • HY-P5333A
    Aβ1-14-εK-KKK-MvF5 Th acetate 99.93%
    Aβ1-14-εK-KKK-MvF5 Th acetate is the acetate salt form of Aβ1-14-εK-KKK-MvF5 Th (HY-P5333). Aβ1-14-εK-KKK-MvF5 Th acetate is part of UB-311 vaccine, that targets the amyloid-beta (Aβ) protein, and ameliorates the Alzheimer’s disease.
    Aβ1-14-εK-KKK-MvF5 Th acetate
  • HY-P5334A
    AADvac 1 TFA
    AADvac 1 TFA is an active tau peptide vaccine for Alzheimer's disease research. AADvac 1 TFA is composed of a regulatory peptide 294KDNIKHVPGGGS305 that drives tau oligomerization conjugated to Aplysia hemocyanin (KLH) and formulated with aluminum hydroxide.
    AADvac 1 TFA
  • HY-P5754B
    TAT-NEP1-40 acetate
    TAT-NEP1-40 acetate is a therapeutic candidate for axonal regeneration and functional recovery after stroke. TAT-NEP1-40 acetate can protect PC12 cells against oxygen and glucose deprivation (OGD) and promote neurite outgrowth. TAT-NEP1-40 acetate protects the brain against ischemia/reperfusion injury through inhibition of neuronal apoptosis. TAT-NEP1-40 acetate can be efficiently delivered into the rat brains.
    TAT-NEP1-40 acetate
  • HY-P5890A
    YVAD-CHO TFA 98.48%
    YVAD-CHO TFA is an interleukin-1β converting enzyme (ICE, caspase 1) inhibitor (Ki: 0.76 nM). YVAD-CHO TFA inhibits mature IL-1β production. YVAD-CHO TFA partially delays motoneurone death in lesioned facial nerve mice.
    YVAD-CHO TFA
  • HY-P99695
    Lerdelimumab 285985-06-0
    Lerdelimumab (CAT-152) is an IgG4 human anti-TGF-β2 recombinant monoclonal antibody. Lerdelimumab can be used as an anti-scarring agent for glaucoma research.
    Lerdelimumab
  • HY-P99886
    Pexelizumab 219685-93-5 99.0%
    Pexelizumab (h5G1. 1-SC) is a humanized scFv monoclonal antibody directed against the C5 complement component. Pexelizumab inhibits apoptosis and leukocyte infiltration. Pexelizumab can be used for the research of cerebral IR injury and myocardial infarction.
    Pexelizumab
  • HY-U00031
    Axomadol 187219-99-4 99.74%
    Axomadol (EN3324) is a centrally active analgesic agent with opioid agonistic properties and inhibitory effects on the reuptake of monoamines.
    Axomadol
  • HY-U00051
    Propiomazine 362-29-8 98.91%
    Propiomazine is an orally active antihistamine agent. Propiomazine is a potent prolactin (PRL) release stimulant, whose effect depends on the antagonism of the dopaminergic system and can inhibit the secretion of luteinizing hormone (LH). Propiomazine is mainly used for anesthesia assistance, mental disorders and anxiety-induced sedation, and can also be used in research related to insomnia.
    Propiomazine
Cat. No. Product Name / Synonyms Application Reactivity